Results 121 to 130 of about 50,558 (217)
Ergotismo inducido por Ritonavir [PDF]
Quisiera hacer algunos comentarios sobre el reporte de caso ‘Ergotismo inducido por ritonavir’ publicado en el número ...
Valdivia-Infantas, Melinda M.
core
The object of this study was to investigate the pharmacokinetics of darunavir-ritonavir and atazanavir-ritonavir once-daily dosing over 72 h (h) following drug intake cessation.
Natalia Seymour +8 more
core +1 more source
Nirmatrelvir/ritonavir is an antiviral agent used against severe acute respiratory syndrome coronavirus 2 infection and inhibits cytochrome P450 3A and P‐glycoprotein.
Kotaro Itohara +14 more
doaj +1 more source
Ewelina Łyszczarz,1 Aleksandra Rezka,1 Dorota Majda,2 Witold Jamróz,1 Aleksander Mendyk1 1Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Lesser Poland Voivodeship,
Łyszczarz E +4 more
doaj
Atazanavir/Ritonavir-Associated Erythema Multiforme in an HIV-1-Positive Patient. [PDF]
Singh RK.
europepmc +1 more source
Evaluating the Effectiveness of Antivirals for COVID-19 in the Post-vaccine, Omicron Era: A Systematic Review and Meta-analysis. [PDF]
Edwards LJ +4 more
europepmc +1 more source
Patent Landscape Report on Ritonavir Dataset.
This report is dedicated to Ritonavir - an antiretroviral drug used to treat HIV infection and AIDS. A major goal of the report is to highlight the technology timeline for Ritonavir from the first filing of this compound to the present filings.
core +1 more source
Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents. [PDF]
Khan MA +8 more
europepmc +1 more source
Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling. [PDF]
Li Q +10 more
europepmc +1 more source

